BCL2L1 and breast cancer: For example, overexpression of BCL2L1 and its protein product, Bcl-xL, has been shown to occur in MI-BC tumors and cell lines and cause resistance to cisplatin and other chemotherapies which are used to treat MI-BC [7,9,10].